CADTH CDEC final recommendation. indication : Type 2 Diabetes mellitus. Empagliflozin (Jardiance -- Boehringer Ingelheim (Canada) Ltd.) :

The CADTH Canadian Drug Expert Committee (CDEC) recommends that empagliflozin be listed for the treatment of type 2 diabetes.

Saved in:

Bibliographic Details
Online Access:	http://www.ncbi.nlm.nih.gov/books/NBK534039/ Full text
Corporate Author:	CADTH Canadian Drug Expert Committee (Author)
Format:	Electronic eBook
Language:	English
Published:	Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2015
Series:	Common drug review clinical review report.
Subjects:	Diabetes Mellitus, Type 2 > drug therapy. Benzhydryl Compounds > therapeutic use. Glucosides > therapeutic use. Sodium-Glucose Transporter 2 Inhibitors > therapeutic use. Cost-Benefit Analysis. Treatment Outcome. Canada.

Internet